文献速递贫血与红细胞疾病MDS 与骨髓增殖性肿瘤

艾曲泊帕治疗中度再生障碍性贫血或单系血细胞减少患者

Eltrombopag for patients with moderate aplastic anemia or uni-lineage cytopenias.
PubMed 文献 · Blood Adv · 2020-01-01

这项前瞻性2期研究纳入34例中度再生障碍性贫血(MAA)或单系血细胞减少(UC)患者,其中MAA 31例、UC 3例,使用艾曲泊帕(EPAG)50-300 mg/d治疗。17例在至少一个可评估系别达到主要终点缓解,贫血改善显著,药物耐受良好;12/17例在中位8个月后因血象稳定停药,多数因血细胞下降需重新用药且均再获缓解。

要点

  • EPAG对MAA/UC患者的多系血细胞减少有效,17/34例在至少一个系别达到缓解。
  • EPAG耐受良好,部分患者可在血象稳定后停药,但多数需重新用药。
  • 治疗中2/34例出现非7号染色体骨髓细胞遗传学异常,无病态造血或原始细胞增多。

核心结论

  • EPAG是MAA/UC患者血细胞减少的一种耐受良好的口服治疗选择。

研究设计与样本

  • 前瞻性2期研究,2012至2017年纳入34例患者,包括31例MAA和3例UC,EPAG剂量从50 mg/d递增至300 mg/d。

主要发现

  • 17例患者在主要终点时至少一个可评估系别达到缓解。
  • 12/17例在中位8个月后因血象稳定或强健停药,多数因血细胞下降重新启用EPAG后均再获缓解。
  • 2/34例在服用EPAG期间出现非7号染色体骨髓细胞遗传学异常,无病态造血或原始细胞增多。
  • 癌症基因的体细胞突变等位基因频率在EPAG治疗期间总体未增加。

关键数值与推荐

  • EPAG剂量从50 mg/d递增至300 mg/d,主要终点在16至20周评估缓解。
  • 缓解患者继续EPAG直至达到定义的强健或稳定血细胞计数。

临床怎么用

  • 对MAA/UC患者可考虑EPAG治疗,起始50 mg/d并逐步递增至300 mg/d。
  • 达到强健或稳定血细胞计数后可尝试停药,但需监测血细胞下降并及时重新启用EPAG。
  • 治疗期间需监测骨髓细胞遗传学异常和癌症基因体细胞突变。

局限性

  • 研究为单臂2期试验,样本量较小(34例),其中UC仅3例。
  • 未设对照组,疗效和安全性需进一步随机研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

There is no standard or widely effective treatment of patients with moderate aplastic anemia (MAA) or hypo-productive uni-lineage cytopenias (UC). Eltrombopag (EPAG), a small molecule thrombopoietin mimetic, has previously been shown to result in durable multi-lineage hematologic responses with low toxicity in patients with refractory severe aplastic anemia (SAA). Its safety and efficacy in MAA are unknown. This prospective phase 2 study enrolled previously untreated and treated MAA and UC patients with clinically relevant cytopenias. EPAG was administered at doses escalating from 50 to 300 mg/d. Hematologic responses were assessed at 16 to 20 weeks. Responding patients were continued on EPAG until reaching defined robust or stable blood counts. EPAG was reinstituted for relapse. Thirty-four patients were enrolled between 2012 and 2017, including 31 with MAA and 3 with UC. Seventeen patients responded in at least 1 eligible lineage by the primary end point. A striking improvement in anemia was observed in a patient with Diamond-Blackfan anemia. EPAG was well tolerated, and it was discontinued for robust or stable blood counts in 12 of 17 patients after a median of 8 months. A majority required re-initiation of EPAG for declining counts, and all regained response. Two of 34 patients developed non-chromosome 7 bone marrow cytogenetic abnormalities while taking EPAG, without dysplasia or increased blasts. Somatic mutation allele frequencies in cancer genes did not increase overall on EPAG. EPAG is a well-tolerated oral treatment of cytopenias in patients with MAA/UC. This trial was registered at www.clinicaltrials.gov as #NCT01328587.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Fan X, Desmond R, Winkler T, et al. Eltrombopag for patients with moderate aplastic anemia or uni-lineage cytopenias. Blood Adv. 2020. PMID: 32330244. doi:10.1182/bloodadvances.2020001657

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。